StrideBio develops gene therapies using its proprietary STRIVETM Capsid Platform to create genetic medicines for patients with life-threatening diseases. The company focuses on delivering curative treatments that address the underlying genetic causes of severe conditions, improving patient outcomes and quality of life.
Funding
$81.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVNHFounders
Product
Problem
Many life-threatening diseases have underlying genetic causes that are not adequately addressed by traditional treatments. These diseases often result in significant morbidity and reduced quality of life for affected individuals. Current therapeutic options may only manage symptoms without targeting the root genetic defect.
Solution
StrideBio is developing gene therapies utilizing its proprietary STRIVE™ Capsid Platform to deliver potentially curative treatments for patients with life-threatening diseases. The company focuses on creating genetic medicines that address the underlying genetic causes of severe conditions. By targeting the genetic source of the disease, StrideBio aims to improve patient outcomes and enhance their quality of life. The STRIVE™ Capsid Platform is designed to optimize the delivery of therapeutic genes to specific cells and tissues within the body.
Target Audience
The primary target audience includes patients suffering from life-threatening diseases with genetic origins, as well as healthcare providers and researchers seeking advanced therapeutic options.
Features
- STRIVE™ Capsid Platform for enhanced gene delivery
- Development of gene therapies targeting underlying genetic causes of diseases
- Focus on life-threatening diseases with unmet medical needs
- AAV Manufacturing capabilities
- Therapeutic pipeline of gene therapy candidates